Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma
The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2011
by Stanford University.
Recruitment status was Active, not recruiting
Study NCT00490009 Information provided by Stanford University
First Received on June 20, 2007. Last Updated on May 18, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Additional conditions recognized in this trial
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, B-Cell
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Tylenol
Benadryl
SSKI
Additional drug interventions recognized in this trial
Acetaminophen
Antibodies, Monoclonal
Diphenhydramine
Iodine-131 anti-B1 antibody
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anesthetics
Anesthetics, Local
Anti-Allergic Agents
Antiemetics
Antineoplastic Agents
Antipyretics
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Gastrointestinal Agents
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Hypnotics and Sedatives
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Stanford University
Corixa Corporation
GlaxoSmithKline
Back to top of Main Content
